Biotech · Private company
Naurex, Inc, an affiliate of Allergan plc
Track this companyFree. Adds Naurex, Inc, an affiliate of Allergan plc to your Dealase workspace and tells you when its record changes.
Clinical trials120 recruiting or active
Pipeline programs7From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline7
- RapastinelPhase 3 · Depressive Disorder, MajorClinicalTrials.gov · fetched Nov 12, 2026
- Rapastinel (225 mg/450 mg IV administration)Phase 2 · Major Depressive DisorderClinicalTrials.gov · fetched Nov 12, 2026
- AlprazolamPhase 1 · Driving PerformanceClinicalTrials.gov · fetched Nov 12, 2026
- KetaminePhase 1 · Human Abuse PotentialClinicalTrials.gov · fetched Nov 12, 2026
- KetaminePhase 1 · Driving PerformanceClinicalTrials.gov · fetched Nov 12, 2026
- RapastinelPhase 1 · Driving PerformanceClinicalTrials.gov · fetched Nov 12, 2026
- RapastinelPhase 1 · Human Abuse PotentialClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials12
- Assessment of Effect of Rapastinel on Driving PerformancePHASE1 · COMPLETED · started Nov 5, 2018ClinicalTrials.gov NCT03814733 · fetched Nov 12, 2026
- Assessment of Abuse Potential of Rapastinel in HumansPHASE1 · COMPLETED · started Nov 1, 2018ClinicalTrials.gov NCT03799900 · fetched Nov 12, 2026
- Study of Adjunctive or Monotherapy Rapastinel Treatment in Patients With Major Depressive Disorder (MDD)PHASE3 · TERMINATED · started Aug 23, 2018ClinicalTrials.gov NCT03668600 · fetched Nov 12, 2026
- Study of Monotherapy Rapastinel in the Prevention of Relapse in Patients With Major Depressive Disorder (MDD)PHASE3 · TERMINATED · started Aug 2, 2018ClinicalTrials.gov NCT03614156 · fetched Nov 12, 2026
- Study of Rapastinel as Monotherapy in Patients With MDDPHASE3 · TERMINATED · started Jun 15, 2018ClinicalTrials.gov NCT03560518 · fetched Nov 12, 2026
- A Study of Rapastinel for Rapid Treatment of Depression and Suicidality in Major Depressive DisorderPHASE2 · TERMINATED · started Dec 15, 2017ClinicalTrials.gov NCT03352453 · fetched Nov 12, 2026
- Long-term Safety Study of Rapastinel as Adjunctive Therapy in Patients With Major Depressive DisorderPHASE3 · COMPLETED · started Feb 3, 2017ClinicalTrials.gov NCT03002077 · fetched Nov 12, 2026
- A Study of Rapastinel as Adjunctive Therapy in the Prevention of Relapse in Patients With Major Depressive DisorderPHASE3 · COMPLETED · started Nov 13, 2016ClinicalTrials.gov NCT02951988 · fetched Nov 12, 2026
- A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-03)PHASE3 · COMPLETED · started Nov 2, 2016ClinicalTrials.gov NCT02943577 · fetched Nov 12, 2026
- A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-02)PHASE3 · COMPLETED · started Nov 1, 2016ClinicalTrials.gov NCT02943564 · fetched Nov 12, 2026
- A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-01)PHASE3 · COMPLETED · started Oct 15, 2016ClinicalTrials.gov NCT02932943 · fetched Nov 12, 2026
- Open Label Extension for GLYX13-C-202, NCT01684163PHASE2 · TERMINATED · started Sep 8, 2014ClinicalTrials.gov NCT02192099 · fetched Nov 12, 2026